Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States and China. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; Tascenso ODT for the treatment of multiple sclerosis; and HND-033 and HND-027 for oncology diseases. It also provides Quetiapine XR to treat Schizophrenia; Dexlansoprazole DR capsules to treat erosive esophagitis and heartburn associated with symptomatic non-erosive gastroesophageal reflux disease; HND-004 for treating diabetes; HND-032 for smoking cessation; and HND-026, a GI drug. The company was founded in 2014 and is headquartered in Tainan City, Taiwan.
तुलना करने के लिए मीट्रिक्स | 6620 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध6620पीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | 26.8x | 0.0x | −0.5x | |
PEG अनुपात | −1.24 | 0.00 | 0.00 | |
क़ीमत/बुक | 4.2x | 0.0x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 12.5x | 0.0x | 2.9x | |
अपसाइड (विश्लेषक लक्ष्य) | 154.5% | 0.0% | 50.4% | |
उचित मूल्य अपसाइड | अनलॉक करें | 0.0% | 9.1% | अनलॉक करें |